Oral glycoprotein IIb/IIIa antagonists: New insights from the SYMPHONY trial

被引：5

作者：

McGuire, DK ^{[1
]}

Newby, LK ^{[1
]}

机构：

[1] Duke Clin Res Inst, Durham, NC 27715 USA

来源：

JOURNAL OF THROMBOSIS AND THROMBOLYSIS | 2000年 / 10卷 / 02期

关键词：

coronary artery disease; platelets; secondary prevention; platelet aggregation inhibitors; glycoprotein IIb/IIIa inhibitors;

D O I：

10.1023/A:1018782708070

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Platelet aggregation plays a central role in the pathophysiology of acute coronary syndromes, and the platelet glycoprotein IIb/IIIa receptor has been identified as the critical final mediator of this process. Antagonists of this receptor used parenterally during both acute coronary syndromes and percutaneous coronary interventions reduce the likelihood of subsequent major cardiac complications. However, after the treatment period little further benefit accrues. Based on these observations and that of the significant benefit of aspirin in cardiovascular secondary prevention, oral glycoprotein IIb/IIIa receptor antagonists are being evaluated with the goal of extending the benefit of glycoprotein IIb/IIIa inhibition into chronic secondary prevention. This paper will review the results of the SYMPHONY study of one such oral agent, sibrafiban, and the current state of the oral glycoprotein IIb/IIIa inhibitor field.

引用

页码：111 / 119

页数：9

共 25 条

[1]

Akkerhuis M, 1999, CIRCULATION, V100, P292

[2]

Alexander J H, 1999, Am Heart J, V138, P175, DOI 10.1016/S0002-8703(99)90000-5

[3] COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS [J].

ALTMAN, R ;

CARRERAS, L ;

DIAZ, R ;

FIGUEROA, E ;

PAOLASSO, E ;

PARODI, JC ;

CADE, JF ;

DONNAN, G ;

EADIE, MJ ;

GAVAGHAN, TP ;

OSULLIVAN, EF ;

PARKIN, D ;

RENNY, JTG ;

SILAGY, C ;

VINAZZER, H ;

ZEKERT, F ;

ADRIAENSEN, H ;

BERTRANDHARDY, JM ;

BRAN, M ;

DAVID, JL ;

DRICOT, J ;

LAVENNEPARDONGE, E ;

LIMET, R ;

LOWENTHAL, A ;

MORIAU, M ;

SCHAPIRA, S ;

SMETS, P ;

SYMOENS, J ;

VERHAEGHE, R ;

VERSTRAETE, M ;

ATALLAH, A ;

BARNETT, H ;

BATISTA, R ;

BLAKELY, J ;

CAIRNS, JA ;

COTE, R ;

CROUCH, J ;

EVANS, G ;

FINDLAY, JM ;

GENT, M ;

LANGLOIS, Y ;

LECLERC, J ;

NORRIS, J ;

PINEO, GF ;

POWERS, PJ ;

ROBERTS, R ;

SCHWARTZ, L ;

SICURELLA, J ;

TAYLOR, W ;

THEROUX, P .

BMJ-BRITISH MEDICAL JOURNAL, 1994, 308 (6921) :81-100

[4]

Bazzino O, 1998, NEW ENGL J MED, V338, P1498

[5]

Bazzino O, 1998, NEW ENGL J MED, V338, P1488

[6] USE OF A MONOCLONAL-ANTIBODY DIRECTED AGAINST THE PLATELET GLYCOPROTEIN IIB/IIIA RECEPTOR IN HIGH-RISK CORONARY ANGIOPLASTY [J].

CALIFF, RM ;

SHADOFF, N ;

VALETT, N ;

BATES, E ;

GALEANA, A ;

KNOPF, W ;

SHAFTEL, J ;

BENDER, MJ ;

AVERSANO, T ;

RAQUENO, J ;

GURBEL, P ;

COWFER, J ;

COHEN, M ;

CROSS, P ;

BITTL, J ;

EDDINGS, K ;

TAYLOR, M ;

DEROSA, K ;

HATTEL, L ;

COOPER, L ;

ESHELMAN, B ;

FINTEL, D ;

NIEMYSKI, P ;

KLEIN, L ;

KENNEDY, H ;

THORNTON, T ;

KEREIAKES, D ;

MARTIN, L ;

ANDERSON, L ;

HIGBY, N ;

ELLIS, S ;

BREZINA, K ;

GEORGE, B ;

CHAPEKIS, A ;

SMITH, D ;

ANWAR, A ;

GERBER, TL ;

PRITCHARD, GL ;

MYLER, R ;

SHAW, R ;

MURPHY, M ;

WARD, K ;

MADIGAN, NP ;

BLANKENSHIP, J ;

HALBERT, M ;

FLANAGAN, C ;

TANNENBAUM, M ;

POLICH, M ;

STEVENSON, C ;

TCHENG, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (14) :956-961

[7]

Cannon CP, 1998, CIRCULATION, V97, P340

[8]

CANNON CP, 1999, 48 SCI SESS AM COLL

[9]

DAVIES MJ, 1990, CIRCULATION, V82, P38

[10] Sustained platelet GP IIb/IIIa blockade with oral orbofiban: Interim pharmacodynamic results of the SOAR study [J].

Ferguson, JJ ;

Deedwania, PC ;

Kereiakes, DJ ;

Fitzgerald, D ;

Anders, RJ ;

Burns, DM ;

Bryzinski, BS .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 31 (02) :185A-185A

← 1 2 3 →